Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Baraclude

- PMLiVE

Teva’s generic Nexium wins US approval

FDA backs copy of AstraZeneca’s heartburn drug

- PMLiVE

Indian generics firm GVK set to be hit with European sales ban

EU regulator raises concerns on conduct of drug studies in India

- PMLiVE

BMS names Giovanni Caforia as new CEO

Current chief operating officer will succeed Lamberto Andreotti in May

- PMLiVE

Regulators to improve cooperation on generic drugs

EMA to spearhead information sharing initiative

- PMLiVE

India turns down patent on Gilead’s Sovaldi

Opens market to cheaper rivals for hepatitis C drug

Bristol Myers Squibb logo

BMS and Lilly to jointly research Opdivo combination

PD-1 inhibitor will be tested with Lilly's galunisertib

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo set for early access in UK

First anti-PD1 to be given fast-track status in the country

Lannett appoints Teva’s Michael Bogda as president

He served as VP of technical operations in for Teva’s Americas division

- PMLiVE

UCB’s $1.53bn generics sale falls through

Advent and Avista Capita back away from bid to acquire Kremers Urban due to unanticipated conflict in timing

Bristol-Myers Squibb (BMS) building

Opdivo to be tested as ‘double immunotherapy’ for tumours

BMS and Ono to test anti-PD-1 in combination with Kyowa Hakko's mogamulizumab

- PMLiVE

PD-1 inhibitors shine at ASH conference

New data suggests the immunotherapy class could be also used for haematological cancers

Bristol-Myers Squibb (BMS) building

BMS to fund hepatitis projects in China and India

Pharma firm awards nine grants to support care for high-risk patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links